On July 29, 2025, bioAffinity Technologies, Inc. announced a new case study showing that its CyPath® Lung successfully detected early-stage lung cancer in a patient previously deemed at low risk. This innovative detection highlights the effectiveness of their technology in cancer diagnostics.